CA
NZ
UK
AU
IND
US
BASECAMP represents a meaningful expansion of scope for Satellos, moving the company's flagship asset from an adult population — where disease progression is often more advanced — into children, where regenerative therapies theoretically have more muscle tissue left to protect. The adult data, which …
The results suggested the GLIX1-olaparib pairing may sidestep that resistance problem. According to the companies, the combination successfully triggered synthetic lethality — a therapeutic effect in which two otherwise survivable cellular deficiencies become lethal in combination — even in tumors that would ordinarily evade …
Platinum-resistant gynecologic cancer represents one of oncology's more difficult treatment settings. Patients who progress after platinum-based chemotherapy — historically the backbone of ovarian cancer treatment — often face a narrowing set of options, with response rates to subsequent lines of therapy typically falling well …
Under the terms of the agreement, the merger is structured to advance nebokitug's ongoing Phase 2 clinical trial in rheumatoid arthritis, a disease area where precision-medicine tools like Scipher's could theoretically improve trial success rates by better matching patients to mechanism. Rheumatoid arthritis remains …
The all-stock structure of the transaction is central to that concern. In reverse-merger-style transactions, existing shareholders of the smaller or weaker-positioned company often end up owning a reduced proportional stake in the combined entity, even when the deal is framed as a strategic combination …
The depth of response drew particular attention from the oncology community. A third of patients — 33% — achieved full clinical remission, a result supported by biomarker evidence showing measurable decreases in gut inflammation and improvements in mucosal integrity. Because immune-mediated enterocolitis frequently forces …
The Memorial Sloan Kettering-led study showed 80% of patients achieving an immunosuppression-free clinical response by day 15, with a third reaching full clinical remission and no therapy-related severe adverse events — a dataset that, on clinical merits alone, would typically be read as a …
Seres enters those discussions with two important assets in hand. First, the company and the FDA have already finalized the protocol for a Phase 2 trial, removing a significant source of regulatory uncertainty that would otherwise complicate partnership negotiations. Second, freshly reported Phase 1b …
NDA acceptance itself is a procedural but consequential milestone: it confirms the FDA has determined the application is sufficiently complete to warrant a full review, without yet indicating a view on the merits of approval. For desmoid tumors specifically, treatment options remain limited, with …
The placement's structure extends well beyond the headline number. Warrants attached to the offering carry the potential to generate a further $6.0 million in proceeds should investors exercise them in full, giving Bone Biologics a path to as much as $9.0 million in combined …
Please wait processing your request...